HealthCare Ventures

Colorescience, Inc. is a skincare brand based in Carlsbad, California, specializing in mineral-based cosmetics and sunscreen products. Founded in 2000, the company offers a range of items, including treatment products, UV protectors, primers, foundations, and enhancers, designed to address various skin concerns such as pigmentation, redness, dark circles, and signs of aging. Colorescience emphasizes high-quality, dermatologist-recommended formulations that incorporate minerals, antioxidants, and botanicals to promote healthy skin and protect against sun damage. The brand markets its products through a network of licensed physicians, luxury spas, retailers, and online platforms, aiming to stand out in the aesthetic makeup segment by providing effective and easy-to-use solutions for diverse skin types.

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of targeted and immuno-oncology therapies for cancer treatment. Founded in 2011 and previously known as HealthCare Pharmaceuticals, the company focuses on identifying and developing molecules that inhibit tumor-promoting pathways and activate the immune system against cancer cells. Its lead program, DKN-01, is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1) and is currently undergoing clinical trials for various cancers, including esophagogastric and gynecologic cancers. Additionally, Leap Therapeutics is advancing its second program, FL-301, which targets Claudin18.2-expressing cells, along with two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative treatments for cancer.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, founded in 2003. It specializes in discovering and developing treatments for sleep apnea and related breathing control disorders. The company has a portfolio of therapeutics, including GAL-021, a small molecule administered intravenously to support respiratory drive in surgical and critical care patients, and GLN-21,160, an oral candidate aimed at treating sleep apnea. Additionally, Galleon is developing GAL-044, a small molecule designed to prevent surgical pain. The company's focus extends to addressing conditions such as ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome, with the goal of improving respiratory health for patients.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Colorescience, Inc. is a skincare brand based in Carlsbad, California, specializing in mineral-based cosmetics and sunscreen products. Founded in 2000, the company offers a range of items, including treatment products, UV protectors, primers, foundations, and enhancers, designed to address various skin concerns such as pigmentation, redness, dark circles, and signs of aging. Colorescience emphasizes high-quality, dermatologist-recommended formulations that incorporate minerals, antioxidants, and botanicals to promote healthy skin and protect against sun damage. The brand markets its products through a network of licensed physicians, luxury spas, retailers, and online platforms, aiming to stand out in the aesthetic makeup segment by providing effective and easy-to-use solutions for diverse skin types.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

DecImmune Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative peptides and monoclonal antibodies aimed at addressing acute tissue-damaging inflammation. The company's therapeutics target conditions such as myocardial infarction, second-degree burns, vascular injury, and reperfusion injury in transplant patients. By focusing on an innate IgM-mediated autoimmune pathway, DecImmune Therapeutics seeks to enhance treatment options for various inflammatory diseases, including diabetic nephropathy and renal ischemia. Founded in 2001 and originally known as Natural Antibodies, Inc., the company rebranded in 2004 to reflect its commitment to advancing therapeutic solutions in the field of inflammation and autoimmunity.

Cleveland HeartLab, Inc. is a specialty clinical laboratory dedicated to the prevention and management of cardiovascular disease (CVD). The company specializes in novel biomarker technologies and develops proprietary diagnostic tests aimed at improving the early identification of individuals at risk for CVD. Cleveland HeartLab offers a range of clinical laboratory services, including an inflammatory panel for CVD, advanced CVD risk profiles, and lipid panels. By focusing on innovative molecular biomarker technologies, the company seeks to enhance the management and reduction of inflammation, ultimately contributing to better cardiovascular health outcomes.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

GITR Inc. develops therapies to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Mosaic Biosciences, Inc. specializes in developing biomaterials for tissue engineering and various medical applications, including drug delivery, regenerative medicine, and stem cell therapies. The company offers a technology platform that supports the incorporation of biological factors such as proteins, peptides, and nucleic acids, facilitating research and development in protein and antibody therapeutics. Mosaic Biosciences collaborates strategically with other organizations, such as Catalyst Biosciences, to enhance its capabilities. Founded in 2009 and based in Boulder, Colorado, the company aims to accelerate the drug discovery process by transforming concepts into development candidates, ultimately improving treatment options for patients.

PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

Tensha Therapeutics specializes in the development of small molecule bromodomain inhibitors, which are a novel class of epigenetic modulators designed to influence gene expression for the treatment of cancer and other serious disorders. Founded on research from Dr. James Bradner at the Dana-Farber Cancer Institute, the company is advancing first-in-class, potent BET bromodomain inhibitors. Its lead program targets conditions such as BRD4-NUT midline carcinoma, acute myeloid leukemia, and multiple myeloma, among others. Tensha Therapeutics operates as a focused company backed by HealthCare Ventures, aiming to address significant unmet medical needs in oncology.

Cleveland HeartLab, Inc. is a specialty clinical laboratory dedicated to the prevention and management of cardiovascular disease (CVD). The company specializes in novel biomarker technologies and develops proprietary diagnostic tests aimed at improving the early identification of individuals at risk for CVD. Cleveland HeartLab offers a range of clinical laboratory services, including an inflammatory panel for CVD, advanced CVD risk profiles, and lipid panels. By focusing on innovative molecular biomarker technologies, the company seeks to enhance the management and reduction of inflammation, ultimately contributing to better cardiovascular health outcomes.

Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics—products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Cool Energy, Inc. specializes in developing renewable energy systems aimed at producing carbon-free power. The company is best known for its ThermoHeart® Engine, which converts low-temperature waste heat from various sources, such as industrial exhaust and power generators, into clean electricity. This engine operates efficiently, generating up to 25 kilowatts of power from each module, with initial testing showing nearly 30% conversion efficiency at a temperature difference of 320°C. The ThermoHeart® Engine utilizes advanced technologies, including self-lubricating seals and high-surface-area heat exchangers, to enhance performance while maintaining low maintenance requirements. Its applications extend to waste heat recovery in commercial and industrial settings, as well as renewable energy systems like biomass and solar thermal power. Founded in 2006 and headquartered in Boulder, Colorado, Cool Energy aims to provide efficient energy solutions that leverage easily accessible thermal resources.

NanoMR specializes in the development of blood diagnostic devices, focusing on the rapid isolation of rare cells from complex biological samples at concentrations as low as one cell per milliliter. The company's innovative immunomagnetic capture system allows for the simultaneous targeting of multiple cell types, enabling the efficient extraction of bacteria and fungi in cases of bloodstream infections, as well as specific cells such as circulating tumor or fetal cells. This process is completed in under 30 minutes, significantly enhancing the speed and accuracy of diagnostics in clinical settings.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Stemgent collaborates with top stem cell scientists to develop cutting-edge technology and solutions for cellular reprogramming, aiming to simplify and support stem cell research. Their products and services are designed by leading researchers in the field, focusing on specialties such as cellular reprogramming, iPS cells, media, human iPSC training, mRNA reprogramming, and custom iPS cell lines. Stemgent's offerings include Pluriton, WIT, StainAlive, and NutriStem, providing researchers with the tools needed to investigate and understand stem cells.

CellNovo is a medical device company focused on diabetes management. The company develops and markets a comprehensive system that includes a cordless micro-pump, an integrated monitoring device, and a cellular handset with a touch screen and embedded blood glucose meter. This innovative system facilitates the automatic transmission of data, allowing for real-time monitoring of patients' conditions through mobile connectivity. By creating an interconnected diabetes management solution, CellNovo aims to enhance the quality of care for individuals living with diabetes.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

DecImmune Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative peptides and monoclonal antibodies aimed at addressing acute tissue-damaging inflammation. The company's therapeutics target conditions such as myocardial infarction, second-degree burns, vascular injury, and reperfusion injury in transplant patients. By focusing on an innate IgM-mediated autoimmune pathway, DecImmune Therapeutics seeks to enhance treatment options for various inflammatory diseases, including diabetic nephropathy and renal ischemia. Founded in 2001 and originally known as Natural Antibodies, Inc., the company rebranded in 2004 to reflect its commitment to advancing therapeutic solutions in the field of inflammation and autoimmunity.

Anchor Therapeutics, Inc. is a biopharmaceutical company specializing in the design and development of peptide modulators for G protein-coupled receptors (GPCRs). The company focuses on creating Pepducin lipopeptide drug candidates that target the intracellular domains of GPCRs, allowing for allosteric modulation of GPCR signaling. Anchor Therapeutics aims to address various medical conditions, including cancer, inflammation, metabolic diseases, heart disease, and pain, through its innovative drug development platform. The company is engaged in pre-clinical research and offers internal programs targeting serious medical indications, such as diabetes and regenerative medicine. Originally incorporated as Ascent Therapeutics in 2006, the company rebranded to Anchor Therapeutics in 2010 and is located in Cambridge, Massachusetts.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

FoldRx Pharmaceuticals, Inc. is focused on the discovery and development of disease-modifying drug therapies targeting diseases associated with protein misfolding and amyloidosis. Established in 2003 and based in Cambridge, Massachusetts, the company has advanced clinical programs aimed at treating genetic neurologic and cardiovascular disorders, specifically transthyretin-associated amyloidoses involving polyneuropathy and cardiomyopathy. Additionally, FoldRx is engaged in research programs addressing conditions such as Parkinson's disease and cystic fibrosis. By developing therapies that address the accumulation of misfolded proteins, the company aims to enhance treatment options for healthcare professionals dealing with these complex disorders.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Stemgent collaborates with top stem cell scientists to develop cutting-edge technology and solutions for cellular reprogramming, aiming to simplify and support stem cell research. Their products and services are designed by leading researchers in the field, focusing on specialties such as cellular reprogramming, iPS cells, media, human iPSC training, mRNA reprogramming, and custom iPS cell lines. Stemgent's offerings include Pluriton, WIT, StainAlive, and NutriStem, providing researchers with the tools needed to investigate and understand stem cells.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

PharmAthene, Inc. is a biodefense company based in Annapolis, Maryland, that specializes in developing medical countermeasures aimed at preventing and treating the health impacts of biological and chemical weapons. Founded in 2001, the company is focused on creating innovative therapies that enhance safety, efficacy, and cost-effectiveness in healthcare. Its key products under development include Valortim, a monoclonal antibody designed for both prophylactic and therapeutic use against anthrax, and Protexia, a recombinant human butyrylcholinesterase intended for treating organophosphate poisoning resulting from exposure to chemical nerve agents. Through these efforts, PharmAthene aims to strengthen national health security.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

InfaCare Pharmaceutical specializes in developing pharmaceuticals tailored for neonatal and pediatric patients, focusing on addressing unmet medical needs in these vulnerable populations. Their portfolio includes treatments for autoimmune and rare diseases across several specialty areas, such as neurology, rheumatology, nephrology, pulmonology, and immunotherapy. A notable product is a heme oxygenase inhibitor designed for the treatment of neonatal hyperbilirubinemia, which can be administered as a single intramuscular injection to both term and pre-term newborns. This innovative treatment helps to break down heme and inhibit bilirubin production, thereby reducing the necessity for phototherapy and exchange transfusions in affected infants. Through its targeted therapies, InfaCare aims to improve health outcomes for children facing critical health challenges.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

Their mission is to provide you with personalized, high-quality care. They are dedicated to helping you through all aspects of your neurological and surgical care. From diagnosis to management, their team is at your service, ensuring our best, for you, each and every time.

Stemgent collaborates with top stem cell scientists to develop cutting-edge technology and solutions for cellular reprogramming, aiming to simplify and support stem cell research. Their products and services are designed by leading researchers in the field, focusing on specialties such as cellular reprogramming, iPS cells, media, human iPSC training, mRNA reprogramming, and custom iPS cell lines. Stemgent's offerings include Pluriton, WIT, StainAlive, and NutriStem, providing researchers with the tools needed to investigate and understand stem cells.

PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

MiddleBrook Pharmaceutical Corporation is a pharmaceutical company focused on developing and commercializing pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

Advancis Pharmaceutical Corporation is dedicated to the development and commercialization of innovative anti-infective products. The company aims to address unmet medical needs in the field of infectious diseases by creating effective therapies that target various pathogens. Through its research and development efforts, Advancis seeks to improve treatment options and patient outcomes in the realm of anti-infective medicine.

CellNovo is a medical device company focused on diabetes management. The company develops and markets a comprehensive system that includes a cordless micro-pump, an integrated monitoring device, and a cellular handset with a touch screen and embedded blood glucose meter. This innovative system facilitates the automatic transmission of data, allowing for real-time monitoring of patients' conditions through mobile connectivity. By creating an interconnected diabetes management solution, CellNovo aims to enhance the quality of care for individuals living with diabetes.

Anexon, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for cardiovascular diseases. The company's primary research centers on an alternatively spliced variant of brain natriuretic peptide known as ANX-042. This therapeutic aims to address the needs of patients suffering from chronic heart failure and kidney dysfunction, representing a significant advancement in the treatment of these conditions. Anexon's commitment to biotechnology underscores its dedication to improving patient outcomes in the cardiovascular field.

Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.

BIKAM Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. BIKAM's research centers on small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins within the retina. Their lead product is an orally active pharmacological chaperone that targets misfolded rod opsin, which is implicated in retinitis pigmentosa, helping to correct its trafficking to the rod cell surface and outer segment. Through its innovative approach, BIKAM Pharmaceuticals strives to provide new treatment options for patients suffering from these serious retinal conditions.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

RedPath Integrated Pathology, LLC is a reference laboratory based in Pittsburgh, Pennsylvania, that specializes in oncology diagnostics. Founded in 2004, the company provides support services to pathologists, clinicians, and patients through its innovative PathFinderTG testing platform. This platform is designed for the early and definitive diagnosis of cancer, utilizing genetic analysis to extract objective and quantitative information from small tissue biopsies, cytology samples, and fluid specimens. RedPath's approach aids in resolving diagnostic challenges, particularly in cases where cancer does not respond as expected to treatment.

Xanthus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, acquisition, and commercialization of small-molecule therapeutics targeting cancer and autoimmune disorders. The company specializes in creating innovative treatments that address unmet medical needs in these critical areas. Through its focused approach, Xanthus Pharmaceuticals aims to advance healthcare solutions that improve patient outcomes and enhance the quality of life for those affected by these diseases.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

FoldRx Pharmaceuticals, Inc. is focused on the discovery and development of disease-modifying drug therapies targeting diseases associated with protein misfolding and amyloidosis. Established in 2003 and based in Cambridge, Massachusetts, the company has advanced clinical programs aimed at treating genetic neurologic and cardiovascular disorders, specifically transthyretin-associated amyloidoses involving polyneuropathy and cardiomyopathy. Additionally, FoldRx is engaged in research programs addressing conditions such as Parkinson's disease and cystic fibrosis. By developing therapies that address the accumulation of misfolded proteins, the company aims to enhance treatment options for healthcare professionals dealing with these complex disorders.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Avidia, Inc. is a biopharmaceutical company based in Mountain View, California, that focuses on the discovery and development of therapeutic proteins. Founded in 2003, the company specializes in creating Avimer therapeutic proteins designed to treat a range of conditions, including autoimmunity, inflammation, oncology, and neurology. Avidia aims to innovate in the field of protein therapeutics to address significant medical needs across these therapeutic areas.

Cardiokine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing pharmaceuticals aimed at preventing and treating cardiovascular diseases. Founded in 2004, the company is known for its lead product, lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. Cardiokine is committed to advancing innovative therapies to address heart failure and related cardiovascular conditions.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

PharmAthene, Inc. is a biodefense company based in Annapolis, Maryland, that specializes in developing medical countermeasures aimed at preventing and treating the health impacts of biological and chemical weapons. Founded in 2001, the company is focused on creating innovative therapies that enhance safety, efficacy, and cost-effectiveness in healthcare. Its key products under development include Valortim, a monoclonal antibody designed for both prophylactic and therapeutic use against anthrax, and Protexia, a recombinant human butyrylcholinesterase intended for treating organophosphate poisoning resulting from exposure to chemical nerve agents. Through these efforts, PharmAthene aims to strengthen national health security.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Cardiokine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing pharmaceuticals aimed at preventing and treating cardiovascular diseases. Founded in 2004, the company is known for its lead product, lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. Cardiokine is committed to advancing innovative therapies to address heart failure and related cardiovascular conditions.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Xanthus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, acquisition, and commercialization of small-molecule therapeutics targeting cancer and autoimmune disorders. The company specializes in creating innovative treatments that address unmet medical needs in these critical areas. Through its focused approach, Xanthus Pharmaceuticals aims to advance healthcare solutions that improve patient outcomes and enhance the quality of life for those affected by these diseases.

Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.

Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).

Xanthus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, acquisition, and commercialization of small-molecule therapeutics targeting cancer and autoimmune disorders. The company specializes in creating innovative treatments that address unmet medical needs in these critical areas. Through its focused approach, Xanthus Pharmaceuticals aims to advance healthcare solutions that improve patient outcomes and enhance the quality of life for those affected by these diseases.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

PharmAthene, Inc. is a biodefense company based in Annapolis, Maryland, that specializes in developing medical countermeasures aimed at preventing and treating the health impacts of biological and chemical weapons. Founded in 2001, the company is focused on creating innovative therapies that enhance safety, efficacy, and cost-effectiveness in healthcare. Its key products under development include Valortim, a monoclonal antibody designed for both prophylactic and therapeutic use against anthrax, and Protexia, a recombinant human butyrylcholinesterase intended for treating organophosphate poisoning resulting from exposure to chemical nerve agents. Through these efforts, PharmAthene aims to strengthen national health security.

Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.

Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).